A new, streamlined AAV purification process that is both universal and scalable could ease commercialization constraint.

Regeneron’s gene therapy for otoferlin-related hearing loss – a genetic cause of deafness – has restored hearing to normal levels in one profoundly deaf child within just 24 weeks.

The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.

An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...

It includes AGTC’s lead candidate AGTC-501 (laruparetigene zosaparvovec), an AAV gene therapy for X-linked retinitis pigmentosa (XLRP), which results from mutations in the RPGR gene, causing ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

As the friar approaches the conclusion of his second term as custos of the Holy Land, he spoke with CNA about his experiences, challenges, and key moments in the role. Father Francesco Patton ...

Keohane alleged officials violated the Eighth Amendment for discontinuing hormone therapy and access to female clothing and grooming products, despite Keohane's prior diagnosis and treatment for ...

We're All Ears for Celebrity Buzz! Please enter a name. Please enter a valid email. Please enter a phone number. Please enter a message. Send the Tip! Us Weekly has affiliate partnerships so we ...

Fresh off the release of a new album called “Hurry Up Tomorrow,” The Weeknd has announced a massive North American stadium tour Award-winning actor Jon Hamm, best known for his roles in “Mad ...